Now that Keytruda has been approved in head and neck cancer, I wouldn't be surprised to see a bigger combination trial in the indication. Btw, the upcoming ASCO-SITC immune monitoring data readout is for melanoma combo using Keytruda. At SITC 2016 in November of last year, a 40% response rate was reported on a sample of 15 patients from this p2b melanoma combo trial, most of whom were biomarker-predicted non-responders to Keytruda. The upcoming ASCO-SITC readout will provide immune monitoring data from these patients.